BidaskClub upgraded shares of STAAR Surgical (NASDAQ:STAA) from a sell rating to a hold rating in a research report sent to investors on Thursday.
A number of other equities analysts have also recently issued reports on the company. Canaccord Genuity increased their target price on STAAR Surgical from $17.50 to $20.00 and gave the stock a buy rating in a report on Friday, November 17th. Benchmark reiterated a buy rating and issued a $21.00 target price on shares of STAAR Surgical in a report on Monday, November 20th. Two research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. The company currently has an average rating of Buy and a consensus target price of $17.67.
STAAR Surgical (NASDAQ STAA) opened at $15.95 on Thursday. STAAR Surgical has a twelve month low of $8.95 and a twelve month high of $17.60. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.82 and a quick ratio of 1.72. The stock has a market capitalization of $660.62, a price-to-earnings ratio of -398.75 and a beta of 1.22.
Large investors have recently modified their holdings of the business. Prudential Financial Inc. bought a new position in STAAR Surgical during the 3rd quarter valued at $138,000. Citadel Advisors LLC bought a new position in STAAR Surgical during the 3rd quarter valued at $172,000. Goldman Sachs Group Inc. lifted its stake in STAAR Surgical by 68.1% during the 2nd quarter. Goldman Sachs Group Inc. now owns 19,073 shares of the medical instruments supplier’s stock valued at $206,000 after acquiring an additional 7,729 shares in the last quarter. Raymond James Financial Services Advisors Inc. bought a new position in STAAR Surgical during the 2nd quarter valued at $214,000. Finally, Voya Investment Management LLC lifted its stake in STAAR Surgical by 15.6% during the 2nd quarter. Voya Investment Management LLC now owns 21,777 shares of the medical instruments supplier’s stock valued at $235,000 after acquiring an additional 2,942 shares in the last quarter. Institutional investors and hedge funds own 79.43% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “STAAR Surgical (STAA) Upgraded to Hold at BidaskClub” was published by Ticker Report and is owned by of Ticker Report. If you are reading this story on another domain, it was copied illegally and republished in violation of United States & international trademark & copyright legislation. The legal version of this story can be accessed at https://www.tickerreport.com/banking-finance/3257122/staar-surgical-staa-upgraded-to-hold-at-bidaskclub.html.
About STAAR Surgical
STAAR Surgical Company designs, develops, manufactures and sells implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. It operates in the ophthalmic surgical market segment. Its principal products are intraocular lenses used in cataract surgery and implantable collamer lenses used in refractive surgery.
Receive News & Ratings for STAAR Surgical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STAAR Surgical and related companies with MarketBeat.com's FREE daily email newsletter.